Just Like France Belgium disagrees with EMA and will veto against Finasteride Finasteride/Dutasteride 6/13/2025
Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.
View this post in the Community →
Similar Community Posts Join
5 / 1000+ resultscommunity Topical finasteride now the safest possible path?
Topical finasteride is considered a safer option for hair regrowth with fewer systemic side effects compared to oral finasteride. Some users report similar efficacy and side effects between topical and oral treatments, while others prefer topical due to reduced systemic exposure.
community Publication concludes finasteride is a associated with a 60% risk of persistent sexual dysfunction.
Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.
community Popular hair loss drug linked to higher suicide risk: compared to non-users, finasteride (Proscar/ Propecia) users have a markedly increased risk of depression, anxiety, and suicidal thoughts. Over 30 years of observation, 19,320 suicides were expected.
Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.
community Anyone excited for CosmeRNA coming this month?
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.
community The ANSM is trying to ban Finasteride
France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.
Related Research
6 / 1000+ results
research Interventions for Female Pattern Hair Loss
Topical minoxidil helps treat female pattern hair loss, but more research needed for other treatments.
research A Comment on the Post-Finasteride Syndrome
The true incidence of post-Finasteride syndrome is unclear, and more research is needed.
research Technological Advances in Anti-Hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation
Collaboration and innovation are key to developing effective, safe hair loss treatments.
research Focused Review on Metal Nanoparticles in Hair Regeneration and Alopecia: Insights into Mechanisms, Assessment Techniques, Toxicity, Regulatory and Intellectual Property Perspectives
Metal nanoparticles show promise for treating hair loss but need more research to ensure safety.
research 26-SNP Panel Aids Guiding Androgenetic Alopecia Therapy and Provides Insight into Mechanisms of Action
Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.
research Regenerative Strategies for Androgenetic Alopecia: Evidence, Mechanisms, and Translational Pathways
New regenerative treatments show promise in improving hair growth for androgenetic alopecia.